Eisai And Abbott Japan Launch RA Drug Humira
This article was originally published in PharmAsia News
Executive Summary
Japanese major drug maker Eisai and Tokyo-based Abbott Japan announced June 17 that they will launch rheumatoid arthritis antibody drug Humira (adalimumab) on June 18. Humira blocks tumor necrosis factor alpha in the body that can cause inflammation and slows progressive joint damages. (Click here for more - Japanese language